Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 2731 AL 2745

Impact of multisession 40Hz tACS on hippocampal perfusion in patients with Alzheimer's disease

Sprugnoli G, Munsch F, Cappon D, Paciorek R, Macone J, Connor A, El Fakhri G, Salvador R, Ruffini G, Donohoe K, Shafi MM, Press D, Alsop DC, Pascual Leone A, Santarnecchi E.

Alzheimers Res Ther. 2021 Dec 20;13(1):203. doi: 10.1186/s13195-021-00922-4.

The Impact of Exercising in the Quality of Life of People with Dementia-Alzheimer's Disease

Dimities M, Xristina F, Theodora-Elesa K, Maria C.

Adv Exp Med Biol. 2021;1339:309-315. doi: 10.1007/978-3-030-78787-5_36.

Evaluation of memory performance in patients with brain disorders following rTMS treatment. A systematic review

Bonotis K, Anargyros K, Liaskopoulos N, Barlogianni AM.

Clin Neurophysiol. 2022 Mar;135:126-153. doi: 10.1016/j.clinph.2021.11.078. Epub 2021 Dec 24.

Dementia research in 2020: moving forward despite the COVID-19 pandemic

Kivipelto M, Mangialasche F.

Lancet Neurol. 2021 Jan;20(1):3-5. doi: 10.1016/S1474-4422(20)30453-1.

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial

Sperling R, Henley D, Aisen PS, Raman R, Donohue MC, Ernstrom K, Rafii MS, Streffer J, Shi Y, Karcher K, Raghavan N, Tymofyeyev Y, Bogert J, Brashear HR, Novak G, Thipphawong J, Saad ZS, Kolb H, Rofael H, Sanga P, Romano G.

JAMA Neurol. 2021 Mar 1;78(3):293-301. doi: 10.1001/jamaneurol.2020.4857.

New Frontiers in the Prevention, Diagnosis, and Treatment of Alzheimer's Disease

Guzman-Martinez L, Calfío C, Farias GA, Vilches C, Prieto R, Maccioni RB.

J Alzheimers Dis. 2021;82(s1):S51-S63. doi: 10.3233/JAD-201059.

Alzheimer Disease Clinical Trials Targeting Amyloid: Lessons Learned From Success in Mice and Failure in Humans

Reiss AB, Montufar N, DeLeon J, Pinkhasov A, Gomolin IH, Glass AD, Arain HA, Stecker MM.

Neurologist. 2021 Mar 4;26(2):52-61. doi: 10.1097/NRL.0000000000000320.

Alzheimer's disease and its treatment by different approaches: A review

Srivastava S, Ahmad R, Khare SK.

Eur J Med Chem. 2021 Apr 15;216:113320. doi: 10.1016/j.ejmech.2021.113320. Epub 2021 Feb 23.

Therapy for Alzheimer's disease: Missing targets and functional markers?

Stoiljkovic M, Horvath TL, Hajós M.

Ageing Res Rev. 2021 Jul;68:101318. doi: 10.1016/j.arr.2021.101318. Epub 2021 Mar 9.

Hypothesis: Intravenous administration of mesenchymal stem cells is effective in the treatment of Alzheimer's disease

Shigematsu K, Takeda T, Komori N, Tahara K, Yamagishi H.

Med Hypotheses. 2021 May;150:110572. doi: 10.1016/j.mehy.2021.110572. Epub 2021 Mar 23.

Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer's Disease Platform

Karelina T, Lerner S, Stepanov A, Meerson M, Demin O.

CPT Pharmacometrics Syst Pharmacol. 2021 Jun;10(6):543-550. doi: 10.1002/psp4.12628. Epub 2021 May 2.

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges

Cano A, Turowski P, Ettcheto M, Duskey JT, Tosi G, Sánchez-López E, García ML, Camins A, Souto EB, Ruiz A, Marquié M, Boada M.

J Nanobiotechnology. 2021 Apr 29;19(1):122. doi: 10.1186/s12951-021-00864-x.

BACE1: from biomarker to Alzheimer's disease therapeutical target

Cervellati C, Valacchi G, Zuliani G.

Aging (Albany NY). 2021 May 11;13(9):12299-12300. doi: 10.18632/aging.203064. Epub 2021 May 11.

The clinical correlation of proinflammatory and anti-inflammatory biomarkers with Alzheimer disease: a meta-analysis

Anuradha U, Kumar A, Singh RK.

Neurol Sci. 2022 Jan;43(1):285-298. doi: 10.1007/s10072-021-05343-7. Epub 2021 May 25.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias